$ATRA News

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Partner Refiles Tabelecleucel Biologics License Application With FDA

HQL: The Rally That Makes Growth Harder (Rating Downgrade)

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics Q1 EPS $(0.29) Beats $(0.41) Estimate, Sales $516.000K Miss $2.850M Estimate

Atara Biotherapeutics Files Prospectus For Offering $79.3M Common Shares

FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate)

Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive

Atara Biotherapeutics Issues Update Following Recent Type A Meeting With FDA To Discuss CRL To BLA For Tabelecleucel Held By Its Partner Pierre Fabre Pharma

Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise

Atara Biotherapeutics shares are trading lower after the company reported worse-than-expected Q4 sales results.

Atara Biotherapeutics shares are trading lower after the company reported worse-than-expected Q4 sales results.

Atara Biotherapeutics Q4 EPS $(0.25) Beats $(0.44) Estimate, Sales $1.595M Miss $2.671M Estimate

The FDA Has Scheduled Type A Meeting To Discuss The Complete Response Letter To Atara Biotherapeutics' Biologics License Application For Tabelecleucel (Tab-cel) Held By Partner Pierre Fabre Pharmaceuticals

Top stock movements in today's session.